Amryt's Skin Disorder Drug Application Review With FDA Extended By Three Months

The FDA made a three-month extension to the review period for Amryt Pharma Plc's AMYT Oleogel-S10 marketing application for junctional and dystrophic epidermolysis bullosa (EB).

  • EB is a rare genetic skin disorder affecting young children and adults for which there is currently no approved treatment.
  • The FDA extended the date to the end of February 2022.
  • The extension allows time to review additional analyses of data previously submitted by Amryt.
  • The FDA also made a new information request regarding existing study data to continue its application evaluation, which the regulator confirmed in June this year had been accepted and granted priority review.
  • The extension has no impact on the priority review status of Oleogel-S10, Amryt said.
  • European regulators are expected to receive an opinion from the Committee for Medicinal Products for Human Use (CHMP) in January 2022.
  • The Company said its previously issued revenue guidance for FY 2021 of $220 million - $225 million is unaffected by the new regulatory timelines.
  • Analyst Reaction: SVB Leerink maintains Outperform rating on Amryt but has lowered the price target to $19.
  • Yesterday, Amryt Pharma announced plans to delist from the Alternative Investment Market (AIM) in London.
  • It said its last day of trading on AIM would be January 10, 2022, noting it would retain its listing on the NASDAQ.
  • Price Action: AMYT shares are down 10.80% at $10.03 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapFDAMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!